Anup Kumar Bhowmick
Chittaranjan National Cancer Institute
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anup Kumar Bhowmick.
Molecular Immunology | 2014
Kuntal Kanti Goswami; Subhasis Barik; Madhurima Sarkar; Anup Kumar Bhowmick; Jaydip Biswas; Anamika Bose; Rathindranath Baral
Tumor-associated macrophages (TAMs) are preferentially M2 skewed and promote tumor growth, angiogenesis, invasion, and/or metastasis. In this study, we have analyzed the in vitro immunomodulatory potential of a non-toxic neem leaf glycoprotein (NLGP) in reprogramming Stage III supraglottic laryngeal tumor cell lysate (SLTCL) induced M2 TAMs to their classical anti-tumor shape (M1). Data generated from this study support that NLGP is effective in preventing the SLTCL induced generation (CD68(+)CD206(+)IL-10(high) to CD68(+)CD206(-)IL-10(low) TAMs) and functions (NO(low) to NO(high), MHC-I(low) to MHC-I(high), CD80(low) to CD80(high)) of pro-tumorous M2 macrophages, which in turn associated with sustained anti-tumor effector functions by promoting cytotoxic T cell activities and suppressing regulatory T cells. Furthermore, our data also suggest that NLGP prevents M2 skewness of TAMs by downregulating phosphorylation of targeted STAT3.
Immunology Letters | 2013
Kuntal Kanti Goswami; Subhasis Barik; Saptak Banerjee; Anup Kumar Bhowmick; Jaydip Biswas; Anamika Bose; Rathindranath Baral
Content of tumor microenvironment (TME) is varied greatly among different types of laryngeal tumors, namely, supraglottic, glottic and subglottic tumors. These three different TMEs shape infiltrating monocytes/macrophages toward M2 genotypes in variable degrees. Results obtained from in vitro studies demonstrated extent of expression of M2 phenotypic features on macrophages was maximum after their exposure to supraglottic laryngeal tumor cell lysates (SLTCL) than glottic or subglottic lysates. Moreover, M2 macrophages generated under influence of SLTCL show less nitric oxide production, greater IL-10: IL-12 ratio and poor antigen presentation. Co-culture of such M2 macrophages with T cells from healthy donors resulted decreased activation of T cells and T cell mediated tumor cell cytotoxicity, than, glottic or subglottic. SLTCL mediated macrophage polarization is STAT3 dependent and might be one of the major factors for severe immune paralysis leading to poor prognosis of supraglottic laryngeal tumor bearer following standard treatment.
Human Immunology | 2012
Krishnendu Chakraborty; Anamika Bose; Kuntal Kanti Goswami; Kalyan Kusum Mukherjee; Shyamal Goswami; Diptendu Ghosh; Tathagata Chakraborty; Koustav Sarkar; Smarajit Pal; Anup Kumar Bhowmick; Jaydip Biswas; Rathindranath Baral
In an aim to rectify dysregulated CC chemokine receptor (CCR5)/ligand (RANTES, MIP-1α, MIP-1β) status of monocytes/macrophages in tongue squamous cell carcinoma (TSCC; n = 12) patients, we have tested interferon α2b (IFNα2b), a novel immunomodulator with wide use in the management of several forms of cancer. IFNα2b can upregulate reduced CCR5 expression and increases the suppressed secretory status of its ligands, as evidenced from in vitro studies on monocytes/macrophages from the peripheral blood of TSCC patients as well as healthy individuals. Isolated monocytes of TSCC patients (n = 5) undergoing chemotherapeutic treatment along with IFNα2b immunotherapy demonstrated significant upregulation in CCR5 expression and secretion of corresponding ligands. These rectifications in receptor/ligand levels are reflected in improved CCR5-dependent migration of monocytes/macrophages after IFNα2b treatment. The rectified chemokine profile and cellular migration translate into better tumoricidal and antigen-presenting functions of these cells. Accordingly, enhanced T-cell-mediated tumor cell killing is demonstrated upon IFNα2b treatment. Translating dual benefits on monocyte/macrophage functions, IFNα2b may emerge as a potential form of immunotherapy for TSCC patients that may be combined with standard chemotherapy for better clinical outcome.
Cellular Oncology | 2017
Sayantan Bhattacharyya; Vasanthakumar Sekar; Biswanath Majumder; Debapriya G. Mehrotra; Samir Banerjee; Anup Kumar Bhowmick; Neyaz Alam; Gautam Kumar Mandal; Jaydip Biswas; Pradip K. Majumder; Nabendu Murmu
PurposeThe tumor suppressor protein p53 is known to control cell cycle arrest and apoptosis. Lupeol is a phytochemical that has been found to induce apoptosis in different cancer types through the extrinsic pathway. As yet, however, its role in the induction of cell cycle arrest and apoptosis through the intrinsic pathway in head and neck cancer has not been investigated. Here, we aimed at understanding the mechanism underlying the antitumor effect of Lupeol in head and neck cancer.MethodsThe antitumor effect of Lupeol on oral and laryngeal carcinomas was assessed using two in vitro 2D cell line models (HEp-2, UPCI:SCC-131) and, subsequently, an ex vivo 3D tumor explant culture platform that maintains key features of the native tumor microenvironment. The mechanism underlying Lupeol-mediated antitumor responses was delineated using MTT, colony formation, flow cytometry, immunofluorescence, Western blotting and immunohistochemistry assays.ResultsWe found that Lupeol induced an enhanced expression of p53 in both cell line models tested and, subsequently, cell cycle arrest at the G1 phase. In addition we found that, following Lupeol treatment, p53 induced Bax expression and activated the intrinsic apoptotic pathway (as measured by Caspase-3 cleavage). Interestingly, Lupeol was also found to trigger G1 cell cycle arrest through up-regulation of the expression of CDKN2A, but not p21, resulting in inhibition of CyclinD1. In an ex vivo platform Lupeol was found to impart a potent antitumor response as defined by inhibition of Ki67 expression, decreased cell viability and concomitant activation (cleavage) of Caspase-3. Finally, we found that Lupeol can re-sensitize primary head and neck squamous cell carcinoma (HNSCC) tumor samples that had clinically progressed under a Cisplatin treatment regimen.ConclusionTogether, our data indicate that Lupeol may orchestrate a bifurcated regulation of neoplastic growth and apoptosis in head and neck cancers and may serve as a promising agent for the management of tumors that have progressed on a platinum-based treatment regimen.
Journal of Nuclear Medicine and Radiation Therapy | 2015
Sayantan Bhattacharyya; Tapas Maji; Dilip Kumar Ray; Anup Kumar Bhowmick; Nabendu Murmu
Background: Cancer of the throat or larynx is one of the predominant cancer types in India and Intensity Mediated Radiation Therapy (IMRT) is the most crucial treatment regimen against the disease. We aimed to examine the effect of Circulating Endothelial Progenitor (CEP) cells in Laryngeal cancer patients undergoing radiation therapy. Patients: Five Laryngeal cancer patients were selected for the work. All patients were suffering from Squamous Cell Carcinoma (SCC) of the glottis and admitted to the institute with CT1 and CT2 stage of tumor with no lymph node metastasis (CN0). After thorough check up the patients were subjected to conventional mononodal radiotherapy (IMRT), fractionated doses to the highest dose (1.8-2 Gy per fraction). Peripheral Blood Mononuclear Cells (PBMC) was isolated from all 5 patients and flow cytometric analysis (using anti CD 44 and CD309 monoclonal antibody) was performed before and after completion of the entire course. Results: Results showed upregulation of the CEPs in all cases after exposure to radiotherapy. Additional immunofluorescence staining confirmed the rapid increase of these cells indicating a strong correlation between the exposure to ionizing radiation and stem cell expression in patients suffering from Glottic cancer. Conclusion: Increase in the CEPs suggests that the tissue damage due to radiation exposure activate the stem cell niche and allures CEPs in the peripheral blood for angiogenesis. Further prospective assessments are warranted.
International Journal of Clinical Oncology | 2011
Mohammad Ashraf; Jaydip Biswas; Jayesh Jha; Sandeep P. Nayak; Vikas Singh; Suparna Majumdar; Anup Kumar Bhowmick; Aniruddha Dam
Tumor Biology | 2015
Sayantan Bhattacharyya; Syamsundar Mandal; Samir Banerjee; Gautam Kumar Mandal; Anup Kumar Bhowmick; Nabendu Murmu
Bengal Journal of Otolaryngology and Head Neck Surgery | 2018
Somesh Mozumder; Shirish Dubey; Aniruddha Dam; Anup Kumar Bhowmick
Bangladesh Journal of Otorhinolaryngology | 2016
Shouvanik Satpathy; Goutam Mondal; Anup Kumar Bhowmick; Aniruddha Dam
Bengal Journal of Otolaryngology and Head Neck Surgery | 2015
Somesh Mozumder; Shirish Dubey; Aniruddha Dam; Anup Kumar Bhowmick